GSK’s Blenrep Comeback On The Cards After Second Trial Win
The DREAMM-8 study was unblinded early thanks to strong interim results, giving Blenrep a shot at returning as a second-line or later treatment for multiple myeloma
The DREAMM-8 study was unblinded early thanks to strong interim results, giving Blenrep a shot at returning as a second-line or later treatment for multiple myeloma